Environmental modulation of phenotype in neuregulin 1 mutants

Tim Karl  
Schizophrenia Research Institute

A. Boucher  
University of Sydney

Brian Dean  
Mental Health Research Institute, anddali@unimelb.edu.au

Xu-Feng Huang  
University of Wollongong, xhuang@uow.edu.au

J Arnold  
University of Sydney

See next page for additional authors
Environmental modulation of phenotype in neuregulin 1 mutants

Abstract
Abstract from the XXVI CINP Congress, Munich, Germany, 13-17 July 2008

Keywords
mutants, environmental, neuregulin, 1, modulation, phenotype

Disciplines
Education | Social and Behavioral Sciences

Publication Details

Authors
Tim Karl, A. Boucher, Brian Dean, Xu-Feng Huang, J Arnold, and P. Schofield

This conference paper is available at Research Online: http://ro.uow.edu.au/sspapers/989
Schizophrenia, basic

**ISS-01.01 Dissection of schizophrenia, bipolar disorder, and depression**

D. Blackwood, University of Edinburgh, Division of Psychiatry, United Kingdom

Depression is common in patients with schizophrenia and it is well established from family studies that rates of depression are increased among relatives of probands with schizophrenia. Family linkage studies in both schizophrenia and bipolar disorder have identified several chromosomal regions likely to contain risk genes for psychiatric illness and some regions overlap in schizophrenia and bipolar families suggesting common susceptibility loci. Candidate gene association studies also suggest that some genes contribute to both affective and non-affective psychoses. Significant association and linkage have been reported with two of the most studied candidates, Neuregulin 1 (NRG1) and Disrupted in Schizophrenia 1 (DISC1) in schizophrenia, schizoaffective disorders, bipolar disorder and depression. However the regions associated with affective and non affective illness differ suggesting that various mutations in one gene may underlie the phenotypic differences. This is supported by an association study of DISC1 using several European cohorts of patients with bipolar disorder and schizophrenia (Hennah 2008). SNPs at two different loci showed significant association with bipolar illness and interaction of these two markers with a third SNP was also detected. These results suggest allelic and locus heterogeneity may underlie the diversity of psychiatric phenotypes. We have examined a third candidate gene for a role in both schizophrenia and affective disorders, GRIK4 a kainate ionotropic glutamate receptor mapped to chromosome 11q23 (Pickard 2006). This gene is disrupted by a chromosomal breakpoint in a patient with schizophrenia and low IQ. A case/control study show a significant association of GRIK4 with both schizophrenia and bipolar disorder and the association with schizophrenia is with markers at different domains of the gene than those showing association with bipolar disorder. The role of these three candidate genes in the pathogenesis of psychoses is not known but we can speculate that they may be involved in fundamental processes of neurodevelopment or neurogenesis increasing risk of mental disorders and the clinical phenotype as expressed in the adult will be the result of modulation by environmental factors and other genetic modifiers.


**ISS-01.02 Immunohistochemical evidence for impaired neuregulin-1 signaling in the prefrontal cortex in schizophrenia and in unipolar depression**

B. Bogerts1, I. Bertram1, H. Dobrowolny1, H.-G. Bernstein1. 1Medizinische Universität Magdeburg, Psychiatrie und Psychotherapie, Germany

**Objective:** Neuregulin-1 proteins play roles in neuronal migration, differentiation and survival of oligodendrocytes. The NRG1 gene codes for at least 15 different isoforms. At least four different haplotypes of the NRG1 gene may be associated with schizophrenia. An abnormal expression pattern of NRG1 mRNA was found in the prefrontal cortex of schizophrenic patients. Here we investigated in post-mortem brains the expression of the two NRG1 isoforms α and β in schizophrenia.

**Methods:** NRG-1α was visualized by immunohistochemistry whole brain serial sections of 22 schizophrenics, 12 patients with affective disorders and 22 matched controls. NRG-1β in brains of 7 schizophrenics, 6 patients with affective disorders and 8 matched controls. NRG-1α immunoreactive material was detected with a polyclonal antiserum against human heregulin/neuregulin (antibody Ab-3 from NeoMarkers), for NRG-1β we used the polyclonal antibody Ab-2 from Neomarkers. The number of profiles of NRG-1α immunoreactive neurons per hemisphere was counted using a computer assisted analysis system. NRG-1β immunoreactive cells in the habenular complex were counted using a light microscope.

**Results:** Normal anatomical distribution showed for NRG-1α only few immunoreactive interneurons located in the prefrontal gray and white matter, whereas NRG-β revealed a widespread immunoreactivity in pyramidal cells and interneurons in the gray matter of DLPFC and anterior cingulate cortex (ACC). In schizophrenia stereologic analysis revealed a significant reduction of NRG-1α cells in the white as well as in the gray cortical matter. In patients with unipolar depression the density of NRG-1α immunoreactive neurons was also significantly reduced in the prefrontal gray matter. In contrast to the 1α-isoreform, NRG-1β immunoreactive interneurons and pyramidal cells in DLPFC and ACC were significantly increased in schizophrenics in comparison to controls. Interneurons of the DLPFC differed significantly between cases of affective disorders and schizophrenics.

**Conclusion:** The diminished expression of NRG-1α in interstitial white matter neurons supports a neurodevelopmental component to schizophrenia (disturbed migration) With regard to NRG-β we assume that the increase of the immunoreactive neurons in schizophrenics leads to a hypofunction of NMDA-receptors via enhanced binding of this NRG-1 isoreform to its receptor, ErbB4 (Hahn et al. 2006). However the increased expression of NRG-1β could also be due to the chronic administration of antipsychotics.  


**ISS-01.04 Testing the functional impact of at-risk haplotypes for schizophrenia with neuroimaging techniques**

M. Wagner, University of Bonn, Psychiatry and Psychotherapy, Germany

Neuregulin 1 has been identified as a potential susceptibility gene for schizophrenia. As with other candidate genes, initial findings have been difficult to replicate, because across studies different haplotypes were associated with the disease (Munafo et al., Schizophrenia Bulletin, 2008). SNP8NRG221533 was the single most significant variant in the original Icelandic haplotype and was included in several replication studies since then. Because neuregulin is implicated in neuronal development and synaptic transmission, we examined the impact of SNP8NRG221533 on neurophysiological, volumetric and functional measures of the brain in schizophrenia. In a study of 100 patients with first-episode of schizophrenia, SNP8_221533 was significantly associated with several measures of executive function (Trail making test B, Digit Symbol Substitution, Word fluency). A subsample of these first episode patients also underwent fMRI with an n-back paradigm. Patients without the at-risk allele at SNP8_221533 showed stronger activations in the left parahippocampal gyrus, the superior frontal gyrus, lateral temporal lobe, precuneus and the right anterior cingulate. In a separate study, we found that hippocampal brain volumes in schizophrenic patients and also in their relatives were affected by the core Icelandic haplotype comprising the same NRG1 SNP (Gruber et al., J. Psychiat Research, in press). Thus, while the association of specific SNPs and haplotypes of the NRG1 gene with schizophrenia may appear less convincing than some years ago, NRG1 variants appear to affect brain functional and structural measures in patients and their relatives, corroborating that frequent polymorphisms (and possibly also rare mutations) in this gene impact on intermediate phenotypes of schizophrenia.

**ISS-01.05 Environmental modulation of phenotype in neuregulin 1 mutants**

T. Karl1, A. Boucher2, B. Dean3, X.-F. Huang4, J. Arnold2, P. Schofield5. 1Garvan Inst of Medical Research, Schizophrenia Research Inst., Sydney, NSW, Australia; 2University of Sydney, Dept. of Pharmacology, Sydney, NSW, Australia; 3Monash Health Research Inst., Rebecca L. Cooper Research Laboratory, Melbourne, VIC, Australia; 4University of Wollongong, School of Health Sciences, Wollongong, NSW, Australia; 5Prince of Wales Medicine Research Inst., Neuroscience, Sydney, NSW, Australia

**Objective:** Schizophrenia has been extensively characterized in terms of its multi-factorial aetiology. It has a heritability of at least 70% and numerous post-mortem studies have highlighted a narrowing of the ventricles, thinned cortex and a reduced size of the lateral ventricles, basal ganglia and thalamus. These findings are consistent with the hypothesis that schizophrenia is a disease of reduced brain growth and organic reduction that occurs in utero and is further compounded by neurodevelopmental abnormalities and environmental factors. This work builds on our previous work which showed that NRG1 (neuregulin 1) is a candidate gene for schizophrenia and may represent a biological endophenotype for this disorder.

**Results:** Our findings confirm the role of neuregulin 1 in brain development, with lower expression in the developing hypothalamus and limbic system. We also demonstrate that neuregulin 1 is expressed in the ventral horn and spinal cord, suggesting its role in neurodevelopment. In addition, we provide evidence that neuregulin 1 is expressed in the prefrontal cortex, and its expression is reduced in schizophrenia. This finding is consistent with previous studies that have shown reduced neuregulin 1 expression in the prefrontal cortex of patients with schizophrenia. Our findings also suggest that neuregulin 1 may play a role in the development of the hippocampus, with reduced expression in hippocampal tissue from patients with schizophrenia. In addition, we demonstrated that neuregulin 1 expression is reduced in the cerebellum, which is consistent with previous studies that have shown reduced cerebellar volume in patients with schizophrenia.

**Conclusion:** Our findings support the hypothesis that neuregulin 1 is a candidate gene for schizophrenia and may represent a biological endophenotype for this disorder. Our results suggest that neuregulin 1 may be involved in the development of the hypothalamus, limbic system, ventral horn, spinal cord, prefrontal cortex, hippocampus and cerebellum, and that reduced expression of neuregulin 1 is associated with schizophrenia.
A variety of environmental risk factors have been proposed as contributing to the development of schizophrenia, including stress and chronic use of drugs of abuse. We hypothesise that subjects with a pre-existing genetic vulnerability for schizophrenia may be more susceptible to these environmental factors.

Methods: Using a multi-factorial animal model strategy, we investigated the neurobehavioural phenotype of male heterozygous TM Nrg1 mutant mice (Nrg1 HET) and their wild type-like (WT) littermates, which (i) were kept in different housing conditions [i.e. standard vs. enriched housing], or (ii) were treated acutely with drugs of abuse [i.e. amphetamine (AMP; 5 mg/kg body weight) or the psychoactive constituent of cannabis, delta-9-tetrahydrocannabinol (THC; 5/10 mg/kg body weight)]. All mice were tested in a variety of tasks for locomotion, exploration, anxiety, working memory and sensorimotor gating. Expression analyses were performed for a variety of receptor systems. Furthermore, c-Fos expression analysis determined neuronal correlates for the behavioural effects of acute THC.

Results: Nrg1 mutants were more susceptible to the stimulation of motor activity and exploration induced by environmental enrichment and its anxiolytic-like effects. Acute AMP treatment induced similar locomotor hyperactivity and disruptions of PPI as well as working memory performance in mutant and WT mice. However, Nrg1 HETs were more sensitive to the locomotor suppressant actions of THC and expressed a greater THC-induced enhancement in %PPI compared to WT mice. Mutants were also more susceptible to the anxiogenic effects of THC. Nrg1 hypomorphs expressed greater basal c-Fos levels in the shell of the nucleus accumbens and the ventral and orbital septum (LSV) and a global increase in cortical serotonin 2A receptors. THC selectively increased c-Fos expression in the LSV, the central nucleus of the amygdala and the paraventricular nucleus of Nrg1 HETs.

Conclusion: These data suggest an interaction between Nrg1 and environmental factors. It appears that variation in the Nrg1 gene alters the sensitivity to the neurobehavioural effects of environmental enrichment and cannabinoids. Importantly, our study adds evidence to face and construct validity of this genetic animal model for schizophrenia.

ISS-02. Dopamine and Clinical Depression: New Findings

ISS-02.01 Dopamine and the regulation of mood and motivational states in humans

M. Leyton
McGill University, Dept. of Psychiatry, Montreal, Quebec, Canada

Objective: Ascending midbrain dopamine neurons project widely, innervating most motor and limbic forebrain regions. Activation of this system has been proposed to influence psychomotor activity, motivational states, and responses to rewards and punishments. Although this research has occurred primarily within the context of studies of substance abuse, Parkinson’s disease, and ADHD, recent findings have rekindled interest in dopamine’s potential role in mood disorders. In the following brief review, the author summarizes the history of these ideas and considers their possible relevance for understanding depression.


Results: Consistent with the animal literature, functional neuroimaging studies in humans indicate that striatal dopaminergic release can be elicited by a wide range of affectively relevant events, including drugs of abuse, drug-related stimuli, food and food cues, motivationally engaging video games, and psychological stressors. The behavioral significance of these changes, though, remains a subject of debate; however, studies of the effects of experimental reductions in dopamine transmission and naturally occurring brain lesions suggest that the most consistent effects are changes in (i) the initiation of movement, (ii) the ability of positively valenced stimuli to elicit and sustain focused attention, and (iii) a sense of well-being and optimistic affect. Unadulterated pleasure, in comparison, is largely unaffected.

Conclusion: The overall pattern of findings suggests that dopamine strongly influences mood-related interest and approach, modestly influences positive emotions, but affects pleasure only tenuously, if at all. Together these effects could influence susceptibility to a wide range of clinically relevant symptoms, particularly psychomotor retardation, loss of interest, and a general sense of dissatisfaction and anhedonia, the inability to experience pleasure (anhedonia), though, likely reflects disturbances to other transmitter systems.

ISS-02.02 Functional connectivity of dopamine, serotonin and norepinephrine neurons as revealed by lesion studies and antidepressant drugs

P. Bléry1, O. Chernoloz1, N. Katz1, F. Chem2, M. El Mansari1, E. Dremencov1
1 University of Ottawa, Inst. of Mental Health Research, Canada

Objective: It is well established that dopamine neurons have anatomical connections with serotonin (5-HT) and norepinephrine (NE) neurons. The importance of the functional connectivity of these reciprocal interactions had been suggested in the past from a variety of studies. However, there was scarce knowledge on the effects of sustained administration of various types of antidepressant drugs on the activity of dopamine neurons, and on the actions of dopaminergic agents effective in the treatment of depression on the activity of 5-HT and NE neurons.

Methods: In vivo electrophysiological recordings of dopamine, 5-HT, and NE neurons were carried in the brain of anesthetized rats after acute, subacute and prolonged administration of antidepressants.

Conclusion: These results document the fact that various classes of antidepressants all have profound effects of the activity of the dopamine neurons giving rise to limbic and/or cortical projections. On the other hand, drugs with dopaminergic properties can also influence other monoaminergic neurons. These results provide a framework to perhaps understand treatment-resistant depression in the perspective that to obtain an optimal response, some negative feedback actions may have to be compensated for, or prevented.

ISS-02.03 Animal models of depression

A. Sulcova1, J. Pivotskacova1
1 Masaryk University, Pharmacology, Brno, Czech Republic

Objective: To establish an animal behavioural model of depression an attention has to be paid to behavioural changes that can be monitored objectively and are reversed by the same treatment that is effective in clinics. The most recognized animal behavioural models of depression in historical sequences are: (a) Bilateral Olfactory Bulbectomy in rodents, (b) Mother-Infant Separation in monkeys, (b) Learned Helplessness in dogs, (c) Forced Swim Test in rodents, (d) Chronic Mild Stress in rodents, (e) Drug-withdrawal-induced anhedonia (f) Tail Suspension Test in mice, (g) Psychosocial stress in rodents (Resident-Intruder test; agonistic behaviour). The results received in potential antidepressant-like activity testing of selected drugs in rodent models of (a) olfactory bulbectomy, and (b) social stress in repeatedly defeated male mice on paired agonistic interactions will be presented.

Methods: The bilateral ablation of the olfactory bulbs was performed by aspiration in the anesthetised rats as described by Leonard and Tuite [1981]. The sham operated rats underwent the identical anaesthetic and drilling procedures as olfactory bulbectomized (OB) animals, but their bulbs were left intact. Experiments were carried out 3 weeks after the surgery. The characteristic locomotor hyperactivity in the open-field test showed by OB rats was measured in the open field (Acti-track infra-red beam based system, Panlab, s. l., Spain). Experiments were carried out 3 weeks after the surgery. The characteristic locomotor hyperactivity in the open-field test showed by OB rats was measured in the open field (Acti-track infra-red beam based system, Panlab, s. l., Spain). Results: (a) At the doses used none of drugs tested for their potential antidepressant-like effects (e.g. felbamate, tiagabine, sertindole, amisulpride) changed locomotor behaviour of sham-operated rats, however they inhibited locomotor hyperactivity in the open field test in OB rats. (b) Compared to control individuals the group-housed mice repeatedly defeated on interaction with aggressive singly-housed male mouse exhibit significantly higher depression of ambulation in the open field test. This was normalized by clinically proven (e.g. citalopram, valproate) as well as potential antidepressants (e.g. felbamate, minocycline).

Conclusion: In conclusion, it is believed that drug testing in both in results presented models could predict their beneficial effect on depression. The work was supported by the research project MSM6002122409.